Research shows Novartis’s Entresto reduces cardiovascular death and heart failure
pharmafile | April 4, 2016 | News story | Research and Development, Sales and Marketing | Entresto, Novartis, Regeneron, Sanofi, cardiovascular, clinical trial, patent
Novartis has announced results from the PARADIGM-HF clinical trial that show that Entresto (sacubitril/valsartan) consistently demonstrated benefit among heart failure patients, in those that were considered clinically stable just as much as it did those who were least-stable.
Results from the trial show that Entresto is just as useful in patients considered stable, as even those patients were identified as at risk of a serious clinical event. In the analysis, over one third of patients were identified as clinically stable, and 20% of those experienced a primary endpoint event (cardiovascular death or heart failure hospitalisation).
The data suggests that Entresto benefitted patients across the board with patients taking the drug having a 20% or greater reduction in cardiovascular death or heart failure hospitalisation compared to those taking enalapril. It showed consistent benefits in reducing the risk of these adverse events, regardless of background therapy.
Vas Narasimhan, global head of drug development and chief medical officer, comments: “This new analysis shows that heart failure patients are never truly stable since in the majority of patients their first clinical event was death. We cannot afford to wait for patients to worsen to use Entresto and improve their chance at a better length of life.”
Entresto was characterised as being of an “innovative nature” in a recent approval granted by NICE.
Sean Murray
Related Content
Novartis receives SMC approval for early breast cancer treatment
Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …
Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …
UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …
